Company
Headquarters: Golden, CO, United States
Employees: 16
CEO: Dr. Michael I. Ruxin M.D.
$8.67 Billion
USD as of Feb. 1, 2022
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. The company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. The company is headquartered in Golden, Colorado.
| Last Financial Reports Date | Dec. 31, 2021 |
| Revenue TTM | $574,789 |
| EBITDA | $-5,147,800 |
| Gross Profit TTM | $256,679 |
| Profit Margin | 76.77% |
| Operating Margin | -928.24% |
| Quarterly Revenue Growth | 706.70% |
OncBioMune Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: OTC: OBMP